Ovesco takes the next step in metabolic bariatric endoscopy and invests in Transduodenal Concepts
Ovesco Endoscopy AG from Tübingen is investing almost € 1 million in the company Trans-Duodenal Concepts GmbH, Mannheim, to jointly promote innovative solutions in the field of metabolic-bariatric endoscopy.
Around one billion people worldwide are affected by metabolic syndrome and its manifestations such as obesity, diabetes, hypertension and fatty liver disease. The Mannheim-based start-up Trans-Duodenal Concepts GmbH (TDC) is developing an innovative, gastroscopically insertable implant that lines the duodenum and parts of the small intestine with a plastic tube. The aim is to prevent the absorption of nutrients in the upper small intestine in order to support weight loss and improve blood sugar management in diabetes patients. The implant combines successful principles of obesity surgery with reversible and non-invasive endoscopic procedures to address the global challenge of metabolic diseases. It has already been tested in preclinical trials and is based on a proven therapy concept. TDC is a technological leader with its innovative implantation method.
With BARS®, Ovesco already has a product in its portfolio that is used for the treatment of complications following bariatric surgery. With the investment of approximately €1 million, Ovesco will receive a stake in TDC and distribution rights for the future product in various regions, thus taking the next step in jointly developing the field of metabolic endoscopy.
About Ovesco Endoscopy AG
The core competence of Ovesco Endoscopy AG lies in the development of endoluminal procedures and technologies that offer patients and users significant advantages in the treatment of gastrointestinal diseases. Our employees work every day to develop innovative products of outstanding quality and exceptional customer benefit and bring them to the clinic. Ovesco develops, produces and distributes instruments and systems for the treatment of gastrointestinal diseases.
